Breast cancer represents a highly heterogeneous malignancy, in which three principal biomarkers, the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), play a central role in molecular classification and therapeutic strategies guidance [11]. This evidence concerns the gene ESR1 and breast cancer.